How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,360 results for

Digoxin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Cohort study: Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure

Cohort study: Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure Article Text Prognosis Cohort

2014 Evidence-Based Medicine (Requires free registration)

22. The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers. (PubMed)

The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers. 27128610 2018 09 25 2018 12 02 2160-7648 3 3 2014 05 Clinical pharmacology in drug development Clin Pharmacol Drug Dev The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers. 202-6 10.1002/cpdd.91 Vourvahis Manoli M Pfizer Global Research and Development, New York, NY, USA. Fang Juanzhi J Pfizer Global Research and Development, Groton, CT, USA. Choo Heng Wee HW Pfizer Clinical Research (...) Unit, Singapore, Singapore. Heera Jayvant J Pfizer Global Research and Development, Groton, CT, USA. eng Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't 2014 02 06 United States Clin Pharmacol Drug Dev 101572899 2160-763X 0 ABCB1 protein, human 0 ATP Binding Cassette Transporter, Subfamily B 0 CCR5 Receptor Antagonists 0 Cyclohexanes 0 Enzyme Inhibitors 0 Triazoles 73K4184T59 Digoxin MD6P741W8A Maraviroc IM ATP Binding Cassette Transporter, Subfamily B antagonists

2018 Clinical pharmacology in drug development

23. Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β-blockers. (PubMed)

Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β-blockers. Digoxin use has been associated with a lower risk of 30-day all-cause admission and readmission in patients with heart failure and reduced ejection fraction (HFrEF).Digoxin use will be associated with improved outcomes in patients with HFrEF receiving β-blockers.Of the 3076 hospitalized Medicare beneficiaries with HFrEF (EF <45%), 1046 received (...) a discharge prescription for β-blockers, of which 634 were not on digoxin. Of the 634, 204 received a new discharge prescription for digoxin. Propensity scores for digoxin use, estimated for each of the 634 patients, were used to assemble a matched cohort of 167 pairs of patients receiving and not receiving digoxin, balanced on 30 baseline characteristics. Matched patients (n = 334) had a mean age of 74 years and were 46% female and 30% African American.30-day all-cause readmission occurred in 15% and 27

Full Text available with Trip Pro

2018 Clinical cardiology

24. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. (PubMed)

No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes mellitus are known to delay gastric emptying (GE). The potential effect of the GLP-1 RA dulaglutide on the pharmacokinetics (PK) of four orally administered drugs and on the pharmacodynamic (PD) effect of warfarin was investigated.In four separate clinical (...) pharmacology studies, digoxin, warfarin, atorvastatin and Ortho-Cyclen® were orally administered to healthy subjects with and without a subcutaneous dose of dulaglutide 1.5 mg. The effect of dulaglutide coadministration was assessed based on the PK parameters of key analytes. For warfarin PD, the effect of dulaglutide on the international normalized ratio (INR) was evaluated.Areas under the concentration-time curves (AUCs) with and without dulaglutide were similar for all analytes except atorvastatin

2018 Clinical pharmacokinetics

25. Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back (PubMed)

Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back 30065596 2018 11 14 1013-9087 30 4 2018 Aug Annals of dermatology Ann Dermatol Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back. 485-488 10.5021/ad.2018.30.4.485 Madsen Marie M https://orcid.org/0000-0001-6579-9376 Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. Pedersen Tanja Xenia TX Department

Full Text available with Trip Pro

2018 Annals of dermatology

26. A Qualitative Study of Digoxin Injection Before Dilation and Evacuation. (PubMed)

A Qualitative Study of Digoxin Injection Before Dilation and Evacuation. We sought to qualitatively understand patients' experiences with digoxin as a step before dilation and evacuation (D&E).We recruited English-speaking women from one abortion health center where digoxin is routinely used before D&E. We interviewed participants one to three weeks after the D&E about physical and emotional experiences with digoxin and understanding of its purpose. Using grounded theory, we analyzed (...) transcripts iteratively, identifying themes from interviews; we stopped recruitment when we reached thematic saturation.We conducted 20 interviews and participants described mixed experiences. Three overarching themes from the qualitative interviews were: (1) physical and emotional discomfort; (2) varied understanding of digoxin's purpose and effects; and (3) reassurance. Most participants described significantly negative experiences with digoxin; however, many participants also described positive aspects

2018 Contraception

27. Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing

Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03433833 Recruitment Status : Not yet recruiting First Posted

2018 Clinical Trials

28. Digoxin Use in Infants with Single Ventricle Physiology: Secondary Analysis of the Pediatric Heart Network Infant Single Ventricle Trial Public Use Dataset. (PubMed)

Digoxin Use in Infants with Single Ventricle Physiology: Secondary Analysis of the Pediatric Heart Network Infant Single Ventricle Trial Public Use Dataset. Digoxin has been associated with reduced interstage mortality after Norwood procedure. We sought to determine its association with survival and change in weight-for-age Z-score (WAZ) before the superior cavopulmonary connection (SCPC) surgery and at 14 months in a heterogeneous group of single ventricle infants. We performed a post-hoc (...) analysis of the Pediatric Heart Network Infant Single Ventricle public use dataset to determine associations between digoxin and survival, transplant-free survival, and change in WAZ pre-SCPC and at 14 months. Sub-analyses of survival and transplant-free survival were performed for subjects who underwent Damus-Kaye-Stansel (DKS)/Norwood. Propensity score weighting was used in Cox hazard-proportion models. Of 229 subjects, 82 (36%) received digoxin and 147 (64%) received no digoxin. Pre-SCPC and 14

2018 Pediatric Cardiology

29. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. (PubMed)

Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. To evaluate the effects of digoxin in patients with the newly described phenotype of heart failure (HF) and mid-range ejection fraction (HFmrEF), attributed to mild left ventricular systolic dysfunction.We carried out a retrospective analysis of the Digitalis Investigation Group (DIG) trial which had 7788 patients available for analysis with a left ventricular ejection fraction (LVEF (...) ) ranging between 3% and 85%. We compared the effect of digoxin to placebo in three mutually exclusive groups of patients defined by LVEF category: <40% (HF with reduced LVEF, HFrEF, n = 5874), 40-49% (HFmrEF, n = 1195) and ≥50% (HF with preserved LVEF, HFpEF, n = 719). The primary outcome was the composite of cardiovascular death or HF hospitalisation. Patients with HFmrEF resembled patients with HFrEF, more than those with HFpEF, with respect to age, sex and aetiology but were more like HFpEF patients

2018 European Journal of Heart Failure

30. Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors (PubMed)

Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors Vascular disrupting agents as DMXAA inhibit tumor growth only for a short period of time followed by rapid tumor regrowth. Among others, hypoxia and presence of transcription factor HIF-1α are responsible for tumors regrowth. The aim of our study was to investigate the inhibition of murine melanoma growth by combining two agents: anti-vascular - DMXAA and the HIF-1α inhibitor (...) - digoxin and explaining the mechanism of action of this combination. After DMXAA treatment tumor size was reduced only for a limited time. After 7 days regrowth of tumors was observed and number of vessels was increased especially in tumor's peripheral areas. DMXAA also induced an influx of immune cells: macrophages, CD8+ cytotoxic lymphocytes, NK cells, CD4+ lymphocytes. Administration of digoxin alone inhibited the growth of tumors. Administration of both agents in the proper sequence significantly

Full Text available with Trip Pro

2018 Scientific reports

31. Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study (PubMed)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study Purpose: The present study compared the risk of ischemic stroke in atrial fibrillation (AF) patients receiving digoxin and amiodarone. Methods: A retrospective cohort study was conducted using the longitudinal population-based database of Taiwan's National Health Insurance program. Patients with AF who received amiodarone or digoxin and were considered to have exposed to study drugs (...) consecutively over 180 days during 2000-2010 were enrolled and divided into three groups: those who received amiodarone, digoxin, and amiodarone plus digoxin. All patients were followed from the index date to the occurrence of ischemic stroke, death, withdrawal from the insurance program, or December 31, 2011. Cox proportional hazard regression models were applied to determine the risk of ischemic stroke and associated risk factors. Results: The amiodarone, digoxin, and amiodarone plus digoxin cohorts

Full Text available with Trip Pro

2018 Frontiers in pharmacology

32. Concurrent renal dysfunction with ischemic heart disease is an important determinant for cardiac and cerebrovascular mortality in patients on chronic digoxin therapy for atrial fibrillation (PubMed)

Concurrent renal dysfunction with ischemic heart disease is an important determinant for cardiac and cerebrovascular mortality in patients on chronic digoxin therapy for atrial fibrillation Major adverse cardiac and cerebrovascular events (MACCEs) are main concerns in patients with atrial fibrillation (AF); however, factors affecting MACCEs remain inconclusive in AF patients chronically treated with digoxin. We investigated the major clinical determinants for fatal MACCEs in AF patients treated (...) with digoxin over a 10-year follow-up period.We analyzed a retrospective cohort of 1,480 AF patients at Eulji University Hospital, Daejeon, South Korea from March 2004 to August 2015. Among this population, 402 consecutive patients receiving chronic digoxin therapy were selected for the study. Data for electrocardiography, medication history, laboratory values including the serum digoxin concentration (SDC) and fatal MACCEs were collected. All data were divided and compared between groups based

Full Text available with Trip Pro

2018 Kidney research and clinical practice

33. Effect of Digoxin on PKM2 Binding to Pro-inflammatory Loci and Innate Immune Inflammatory Responses in the Peripheral Blood.

Effect of Digoxin on PKM2 Binding to Pro-inflammatory Loci and Innate Immune Inflammatory Responses in the Peripheral Blood. Effect of Digoxin on PKM2 Binding to Pro-inflammatory Loci and Innate Immune Inflammatory Responses in the Peripheral Blood. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Digoxin on PKM2 Binding to Pro-inflammatory Loci and Innate Immune Inflammatory Responses in the Peripheral Blood. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

34. Improvement of Adequate Digoxin Dosage: An Application of Machine Learning Approach (PubMed)

Improvement of Adequate Digoxin Dosage: An Application of Machine Learning Approach Digoxin is a high-alert medication because of its narrow therapeutic range and high drug-to-drug interactions (DDIs). Approximately 50% of digoxin toxicity cases are preventable, which motivated us to improve the treatment outcomes of digoxin. The objective of this study is to apply machine learning techniques to predict the appropriateness of initial digoxin dosage. A total of 307 inpatients who had (...) their conditions treated with digoxin between 2004 and 2013 at a medical center in Taiwan were collected in the study. Ten independent variables, including demographic information, laboratory data, and whether the patients had CHF were also noted. A patient with serum digoxin concentration being controlled at 0.5-0.9 ng/mL after his/her initial digoxin dosage was defined as having an appropriate use of digoxin; otherwise, a patient was defined as having an inappropriate use of digoxin. Weka 3.7.3, an open

Full Text available with Trip Pro

2018 Journal of healthcare engineering

35. Effect of green tea catechins on the pharmacokinetics of digoxin in humans (PubMed)

Effect of green tea catechins on the pharmacokinetics of digoxin in humans Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1. This study aimed to investigate the effect of green tea on the pharmacokinetics of digoxin, a typical probe drug of p-gp.Sixteen healthy volunteers participated in this study. At Day 1, 0.5 mg of digoxin was administered via oral route. After a 14-day washout period, 630 mg of green tea catechins (GTC (...) ) was administered via oral route, followed by 0.5 mg of digoxin 1 hour later. From Day 16 through Day 28, 630 mg of GTC was administered alone. At Day 29, 630 mg of GTC and 0.5 mg of digoxin were administered in the same way as Day 15. Blood samples for the pharmacokinetic assessments of digoxin were collected up to 8 hours after each dose. Pharmacokinetic parameters were estimated by noncompartmental analysis. Area under the curve (AUC) and peak plasma concentration (Cmax) were compared using mixed effect

Full Text available with Trip Pro

2018 Drug design, development and therapy

36. PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin (PubMed)

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin According to current US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidance documents, physiologically based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict drug-drug interactions (DDIs) and may offer an alternative to dedicated clinical trials. This study provides whole-body PBPK (...) models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin within the Open Systems Pharmacology (OSP) Suite. All models were built independently, coupled using reported interaction parameters, and mutually evaluated to verify their predictive performance by simulating published clinical DDI studies. In total, 112 studies were used for model development and 57 studies for DDI prediction. 93% of the predicted area under the plasma concentration-time curve (AUC) ratios and 94

Full Text available with Trip Pro

2018 CPT: pharmacometrics & systems pharmacology

37. "Old remedies to heal the liver: novel effects of digoxin in hepatic sterile inflammation". (PubMed)

"Old remedies to heal the liver: novel effects of digoxin in hepatic sterile inflammation". 30033594 2019 01 29 1527-3350 69 2 2019 Feb Hepatology (Baltimore, Md.) Hepatology Old Remedies to Heal the Liver: Novel Effects of Digoxin in Hepatic Sterile Inflammation. 904-906 10.1002/hep.30188 Arab Juan P JP Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. Department of Gastroenterology, School of Medicine, Pontifical Catholic University of Chile, Santiago, Chile. Arrese

2018 Hepatology

38. Mortality in heart failure with atrial fibrillation: role of digoxin and diuretics. (PubMed)

Mortality in heart failure with atrial fibrillation: role of digoxin and diuretics. The impact of atrial fibrillation (AF) on mortality of patients with heart failure (HF) has been established. Nevertheless, the effect of some factors in mortality, such as digoxin or diuretic use, remains controversial. This study aims at assessing mortality in community-dwelling patients with stable HF related to AF and determines the relation of these drugs with prognosis.Community-based cohort study of HF (...) ). At the end of the study, 25.8% patients had died, and mortality was higher when AF was present (28.8% vs 24.1%, P < 0.001, respectively). Multivariate model confirmed the higher risk of death for AF patients (HR 1.10 95%, CI 1.02-1.19). Digoxin and diuretics were not associated with higher mortality in AF patients (HR 1.04 95% CI 0.92-1.18 and HR 1.04 95% CI 0.85-1.26, respectively).An excess of mortality in HF patients with AF was found in a large retrospective community-based cohort. Digoxin

2018 European journal of clinical investigation

39. The effect of different digoxin concentrations on heart tissue and antioxidant status in iron-overloaded rats (PubMed)

The effect of different digoxin concentrations on heart tissue and antioxidant status in iron-overloaded rats Thalassaemia is a hereditary disorder and has an economic burden on patients and the government. The most prevalent complication in these patients is iron overload which is followed by cardiomyopathy. Digoxin is considered as a treatment against heart failure in thalassaemia. The present study evaluated the effect of two digoxin concentrations on iron content and antioxidative defense (...) in cardiac tissue of iron-overloaded rats.The study was conducted on 48 rats which were divided into 6 groups. Group 1 was the control group and did not receive any treatment and group 2 was the iron overload group. In addition groups 3 and 4 were the digoxin control groups which received 1 and 5 mg/kg/day of digoxin, respectively. Groups 5 and 6 received 1 and 5 mg/kg/day of digoxin plus iron-dextran, respectively. After 1 month, malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase

Full Text available with Trip Pro

2018 ARYA atherosclerosis

40. A DNA-Based Assay for Digoxin Detection (PubMed)

A DNA-Based Assay for Digoxin Detection The most common method for quantifying small-molecule drugs in blood samples is by liquid chromatography in combination with mass spectrometry. Few immuno-based assays are available for the detection of small-molecule drugs in blood. Here we report on a homogeneous assay that enables detection of the concentration of digoxin spiked into in a plasma sample. The assay is based on a shift in the equilibrium of a DNA strand displacement competition reaction

Full Text available with Trip Pro

2018 Biosensors

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>